OPTHEA LIMITED

0.00%

60.0¢

Market Cap $820.7M

Healthcare Biotechnology

Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The... Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Latest Threads

Tag

Subject

OPT

Opthea Chances as a treament for Lymphangioleiomyomatosis

08/05/26

2.8K

08/05/26

Last post Ollie3039

2.8K

OPT

Ann: Long Term Suspended Entities

06/05/26

8.0K

06/05/26

Last post simons77

8.0K

OPT

Ann: Quarterly Activities/Appendix 4C Cash Flow Report

01/05/26

546

01/05/26

Last post FreeFromStyle

546

OPT

Ann: Long Term Suspended Entities

18/04/26

1.2K

18/04/26

Last post SpruceMoosey

1.2K

OPT

Ann: Voluntary suspension

10 11 12

28/03/26

713

270K

28/03/26

Last post DwellingDeep

713

270K

OPT

Ann: Appendix 4D and Half Year Report for period 31 Dec 2025

09/03/26

2.9K

09/03/26

Last post Ollie3039

2.9K

OPT

Ann: Quarterly Activities/Appendix 4C Cash Flow Report

30/01/26

1.8K

30/01/26

Last post mapp

1.8K

OPT

What really happened to ph3 trial failure

22/01/26

9.0K

22/01/26

Last post slambo

9.0K

See All Discussions

Timeline

Quarterly Activities/Appendix 4C Cash Flow Report
30 Apr 09:08	Share

Long Term Suspended Entities
17 Apr 14:52	Share

Appendix 4D and Half Year Report for period 31 Dec 2025
02 Mar 08:15	Share

Quarterly Activities/Appendix 4C Cash Flow Report
30 Jan 09:14	Share

Long Term Suspended Entities
22 Jan 16:31	Share

Notification of cessation of securities - OPT
15 Jan 15:28	Share

Change of Director's Interest Notice - KC & LG
23 Dec 08:44	Share

Notification regarding unquoted securities - OPT
19 Dec 12:21	Share

Investor Update Presentation
17 Dec 10:02	Share

Notice of Market Update
12 Dec 09:27	Share

Change in substantial holding
08 Dec 08:19	Share

Voluntary delisting from Nasdaq takes effect
21 Nov 09:21	Share

Results of AGM
11 Nov 11:17	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Oct 09:46	Share

Opthea announces intention to delist from Nasdaq
30 Oct 09:31	Share

Appointment of Company Secretary and CFO
27 Oct 09:48	Share

Long Term Suspended Entities
15 Oct 16:15	Share

Notice of Annual General Meeting/Proxy Form
10 Oct 08:30	Share

Opthea Receives A$10.8 million R&D Tax Incentive
06 Oct 08:36	Share

Opthea - Annual General Meeting Date
16 Sep 09:46	Share

2025 Corporate Governance Statement
15 Sep 15:12	Share

Annual Report to shareholders
15 Sep 15:10	Share

S&P DJI Announces September 2025 Quarterly Rebalance
05 Sep 17:09	Share

Application for quotation of securities - OPT
05 Sep 16:47	Share

Preliminary Final Report
29 Aug 19:16	Share

Ceasing to be a substantial holder
22 Aug 08:15	Share

Becoming a substantial holder
21 Aug 18:52	Share

Corporate Update Investor Call
20 Aug 09:02	Share

Application for quotation of securities - OPT
19 Aug 11:43	Share

Opthea Provides Corporate Update
19 Aug 08:39	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.


Last 60.0¢		Change 0.000(0.00%)		Mkt cap ! $820.7M

Open	High	Low	Volume
0.0¢	0.0¢	0.0¢	0

Last trade - 10.00am 11/05/2026 (20 minute delay)

OPT (ASX) Chart

Day chart unavailable

OPTHEA LIMITED

Corporate Spotlight
Not Yet Available

Latest Threads

Future Investing Starts with Understanding What Comes Next

Timeline

Featured News

Latest Articles

Opthea, with shares still suspended, cuts workforce by 65% after drug trials cancelled

Troubled biotech stock Opthea (ASX:OPT), still in the process of crisis talks with investors, has flagged a workforce reduction of -65%.

Opthea's Phase 3 trial results fail to help patients, future of company at risk

It mightn't be too surprising that Opthea applied for a voluntary suspension last week ahead of Monday's Phase 3 trial results.

Biotech smallcap Opthea eyes 5% jump as key drug of interest validated in paper

Opthea has jumped to 77cps after having its diabetic eye drug of interest further validated as a potential treatment in a scientific paper.

Top Stories

Featured News

OPTHEA LIMITED

Corporate SpotlightNot Yet Available

Latest Threads

Future Investing Starts with Understanding What Comes Next

Timeline

Featured News

Latest Articles

Opthea, with shares still suspended, cuts workforce by 65% after drug trials cancelled

Troubled biotech stock Opthea (ASX:OPT), still in the process of crisis talks with investors, has flagged a workforce reduction of -65%.

Opthea's Phase 3 trial results fail to help patients, future of company at risk

It mightn't be too surprising that Opthea applied for a voluntary suspension last week ahead of Monday's Phase 3 trial results.

Biotech smallcap Opthea eyes 5% jump as key drug of interest validated in paper

Opthea has jumped to 77cps after having its diabetic eye drug of interest further validated as a potential treatment in a scientific paper.

Top Stories

Featured News

Corporate Spotlight
Not Yet Available